Jefferies initiated coverage on EQRx with a new price target
$EQRX
Biotechnology: Pharmaceutical Preparations
Health Care
Jefferies initiated coverage of EQRx with a rating of Buy and set a new price target of $5.60
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/14/2022 | Neutral → Underweight | JP Morgan | |
| 11/11/2022 | $8.00 → $5.00 | Buy → Neutral | Goldman |
| 11/11/2022 | $5.60 → $3.20 | Buy → Hold | Jefferies |
| 8/16/2022 | $5.50 | Neutral | JP Morgan |
| 6/13/2022 | $8.00 | Buy | Goldman |
| 4/22/2022 | Outperform | Cowen | |
| 3/18/2022 | $5.60 | Buy | Jefferies |
JP Morgan downgraded EQRx from Neutral to Underweight
Goldman downgraded EQRx from Buy to Neutral and set a new price target of $5.00 from $8.00 previously
Jefferies downgraded EQRx from Buy to Hold and set a new price target of $3.20 from $5.60 previously
SC 13G/A - EQRx, Inc. (0001843762) (Subject)
SC 13D/A - EQRx, Inc. (0001843762) (Subject)
SC 13D/A - EQRx, Inc. (0001843762) (Subject)
Revolution Medicines Expects to Conduct Late-Stage Development of RAS(ON) Inhibitor Drug Candidate Pipeline Supported by Fortified Balance Sheet Agreement is the Result of a Rigorous Process Conducted by Independent Transaction Committee of EQRx Board to Consider Strategic Alternatives to Maximize Value for EQRx Stockholders Transaction Expected to Close in November 2023 REDWOOD CITY, Calif. and CAMBRIDGE, Mass., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. ("Revolution Medicines" or the "Company") (NASDAQ:RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, and EQRx, Inc. ("EQRx") (NASDAQ:EQRX) today announced a definitive agr
Company to utilize significant scale of capital and team to advance a pipeline of clinically differentiated, high-value therapiesPrioritizing development of lerociclib (CDK 4/6 inhibitor); initiated Phase 3 trial in first-line advanced endometrial cancer; enrollment in Phase 2 trial in first- and second-line advanced breast cancer near completion, providing a foundation for future combination development opportunitiesSeeking commercialization partnerships for aumolertinib (third-generation EGFR inhibitor)Terminating license agreements for sugemalimab (anti-PD-L1 antibody), nofazinlimab (anti-PD-1 antibody) and EQ121 (JAK-1 inhibitor)$1.3 billion in cash, cash equivalents and short-term inves
CAMBRIDGE, Mass., April 27, 2023 (GLOBE NEWSWIRE) -- EQRx, Inc. (NASDAQ:EQRX), a new type of pharmaceutical company committed to developing and expanding access to innovative medicines for some of the most prevalent disease areas, including cancer and immune-inflammatory conditions, today announced it will host a conference call and webcast on Monday, May 8, 2023, at 4:30 p.m. ET to report its first quarter 2023 financial results and provide a business update. A live webcast of the call will be available on the "Investor Relations" page of the Company's website at https://investors.eqrx.com/news-events/events-presentations. To access the call by phone, participants should visit this link
NEW YORK, Aug. 05, 2023 (GLOBE NEWSWIRE) -- EQRx, Inc. (NASDAQ:EQRX) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of EQRX to Revolution Medicines, Inc. Under the terms of the proposed merger, EQRX shareholders will receive the number of shares of Revolution Medicines, Inc. stock equal to the sum of ~7.69M Revolution Medicines, Inc. shares plus a number of shares equal to $870M divided by a price that is a 6% discount to the 5-day volume-weighted average Revolution Medicines Inc. share price measured in close proximity to the stockholder vote. If you are an EQRX investor, and would like additional information abo
Revolution Medicines Expects to Conduct Late-Stage Development of RAS(ON) Inhibitor Drug Candidate Pipeline Supported by Fortified Balance Sheet Agreement is the Result of a Rigorous Process Conducted by Independent Transaction Committee of EQRx Board to Consider Strategic Alternatives to Maximize Value for EQRx Stockholders Transaction Expected to Close in November 2023 REDWOOD CITY, Calif. and CAMBRIDGE, Mass., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. ("Revolution Medicines" or the "Company") (NASDAQ:RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, and EQRx, Inc. ("EQRx") (NASDAQ:EQRX) today announced a definitive agr
Company to utilize significant scale of capital and team to advance a pipeline of clinically differentiated, high-value therapiesPrioritizing development of lerociclib (CDK 4/6 inhibitor); initiated Phase 3 trial in first-line advanced endometrial cancer; enrollment in Phase 2 trial in first- and second-line advanced breast cancer near completion, providing a foundation for future combination development opportunitiesSeeking commercialization partnerships for aumolertinib (third-generation EGFR inhibitor)Terminating license agreements for sugemalimab (anti-PD-L1 antibody), nofazinlimab (anti-PD-1 antibody) and EQ121 (JAK-1 inhibitor)$1.3 billion in cash, cash equivalents and short-term inves
15-12G - EQRx, Inc. (0001843762) (Filer)
EFFECT - EQRx, Inc. (0001843762) (Filer)
EFFECT - EQRx, Inc. (0001843762) (Filer)
4 - EQRx, Inc. (0001843762) (Issuer)
4 - EQRx, Inc. (0001843762) (Issuer)
4 - EQRx, Inc. (0001843762) (Issuer)
Revolution Medicines, Inc. (NASDAQ:RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, and EQRx, Inc. (NASDAQ:EQRX), announced that earlier today, at their respective special meetings, Revolution Medicines and EQRx stockholders voted to approve Revolution Medicines' proposed acquisition of EQRx. The final votes will be certified by an independent inspector of elections for each company and publicly reported following this certification. The transaction is expected to close in November 2023, as soon as all customary closing conditions are satisfied.Upon completion of the transaction, each share of common stock of EQRx issued and outstanding immedia
Gainers Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) shares gained 188.8% to $4.13. The stock is now on the Regulation SHO "threshold security" list. Motorsport Games Inc. (NASDAQ:MSGM) gained 132% to $7.97. Yellow Corporation (NASDAQ:YELL) surged 79% to $3.15 on continued volatility after the company reportedly ceased operations and is preparing for bankruptcy. T Stamp Inc. (NASDAQ:IDAI) shares rose 55% to $1.29. Trust Stamp announced a 31% increase in its financial services customer base in the last 6-months. American Superconductor Corporation (NASDAQ:AMSC) climbed 50.1% to $15.13 amid claims of a new superconductor from a group of physicists. ABVC BioPharma, Inc. (NASDAQ:ABVC